卵巢储备作为激素受体阳性HER2阴性淋巴结阳性乳腺癌辅助化疗获益指标:SWOG S1007(RxPONDER)研究
RxPONDER试验比较内分泌治疗(ET)联合或不联合化疗(CET)在激素受体阳性/HER2阴性、复发评分≤25的乳腺癌患者中的疗效。本分析在1556例<55岁参与者中检测治疗前卵巢储备相关激素,发现AMH≥10 pg/ml与CET获益显著交互(Padj=0.0034),该组CET较ET alone改善IDFS(HR 0.46,95%CI 0.33-0.65,Padj=0.00012),而AMH<10 pg/ml组无获益(HR 1.27,95%CI 0.81-1.99,Padj=0.47)。
要点
- AMH≥10 pg/ml提示CET可显著改善IDFS,而AMH<10 pg/ml者未观察到CET获益。
- AMH对CET获益的指示作用优于绝经状态、年龄或其他激素。
- 卵巢储备标志物可能优化HR阳性/HER2阴性淋巴结阳性乳腺癌的CET选择。
核心结论
- 在<55岁绝经前患者中,基线AMH<10 pg/ml者未从CET获益。
- AMH是比绝经状态、年龄或其他激素更好的CET获益指标。
- 卵巢储备指标可能优化CET的患者选择。
研究设计与样本
- RxPONDER为3期试验,比较ET alone与CET在HR阳性/HER2阴性、RS≤25乳腺癌患者中的疗效。
- 本分析 blinded 检测1556例<55岁参与者的治疗前血清雌二醇、孕酮、FSH、LH、AMH和INHB,所有标志物采用预设cut point。
主要发现
- 基线雌二醇、孕酮、LH和FSH不能预测CET获益。
- AMH≥10 pg/ml与化疗获益对IDFS存在显著交互(Padj=0.0034)。
- AMH≥10 pg/ml组(64%)CET较ET alone改善IDFS(HR 0.46,95%CI 0.33-0.65,Padj=0.00012)。
- AMH<10 pg/ml组(36%)CET无获益(HR 1.27,95%CI 0.81-1.99,Padj=0.47)。
- DRFS显示AMH类似模式,超敏INHB(pg/ml范围)也可预测CET获益。
关键数值与推荐
- AMH cut point为10 pg/ml(正常卵巢储备cut-off)。
- AMH≥10 pg/ml组CET vs ET alone的IDFS HR 0.46(95%CI 0.33-0.65,Padj=0.00012)。
- AMH<10 pg/ml组CET vs ET alone的IDFS HR 1.27(95%CI 0.81-1.99,Padj=0.47)。
- AMH与CET获益交互的Padj=0.0034。
临床怎么用
- 对<55岁绝经前HR阳性/HER2阴性淋巴结阳性乳腺癌患者,可检测基线AMH辅助判断CET获益。
- AMH≥10 pg/ml提示CET可能改善IDFS,AMH<10 pg/ml提示CET可能无获益。
- AMH可能优于绝经状态、年龄或其他激素用于筛选CET获益人群。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3 RxPONDER trial compared endocrine therapy (ET) alone or with chemotherapy (CET) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with recurrence score (RS) ≤25. CET benefit for the primary outcome, invasive disease-free survival (IDFS), was limited to premenopausal women who largely did not receive ovarian function suppression. In this study, we assessed hormones associated with ovarian reserve to further refine the prediction of CET benefit. PATIENTS AND METHODS: Pretreatment serum estradiol, progesterone, follicule-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and inhibin B (INHB) were assessed in a blinded fashion from 1556 participants aged <55 years. All markers used a predefined cut point. Associations with markers and IDFS and distant relapse-free survival (DRFS) were evaluated for prediction of CET benefit, adjusting for RS. Cox regression analyses of assigned treatment and its interaction with potential markers were adjusted for multiplicity. RESULTS: Baseline estradiol, progesterone, LH, and FSH were not predictive for CET benefit. AMH ≥10 pg/ml showed significant interaction with chemotherapy benefit for IDFS (Padj = 0.0034). In 64% of women with AMH ≥10 pg/ml (cut-off for normal ovarian reserve), IDFS was superior with CET compared with ET alone [hazard ratio (HR) 0.46, 95% CI 0.33-0.65, Padj = 0.00012], whereas CET was not beneficial in the 36% with low ovarian reserve (AMH <10 pg/ml; HR 1.27, 95% CI 0.81-1.99, Padj = 0.47). DRFS showed a similar pattern of results for AMH. Ultrasensitive INHB measured in the pg/ml range was also predictive of CET benefit. CONCLUSION: Among premenopausal patients aged <55 years, participants with baseline AMH <10 pg/ml did not benefit from CET. AMH was a significantly better indicator of CET benefit than menopause status, age, or other hormones. Measures of ovarian reserve may refine the selection of patients for CET.
引用
- Kalinsky K, Barlow WE, Pathak HB, et al. Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER). Ann Oncol. 2026. PMID: 42613139. doi:10.1016/j.annonc.2026.05.697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。